Teva's CGRP mi­graine drug aces PhI­II while ri­vals pile up at the FDA fin­ish line

Pos­i­tive late-stage da­ta are start­ing to pile up in the CGRP mi­graine drug cat­e­go­ry, like­ly sig­nal­ing a sud­den in­flux of new drugs with re­mark­ably sim­i­lar da­ta sets look­ing to carve up the mar­ket in their field.

The lat­est en­try: Te­va, which bad­ly needs some good news af­ter a se­ries of cor­po­rate and R&D set­backs, says its Phase III HA­LO study came through on fre­manezum­ab, set­ting up a new FDA ap­pli­ca­tion that will fol­low short­ly as it pre­pares to pub­lish an­oth­er batch of Phase III da­ta on episod­ic mi­graine in a mat­ter of weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER